Everolimus (RAD001) therapy of giant cell astrocytomas in patients with tuberous sclerosis complex.

Trial Profile

Everolimus (RAD001) therapy of giant cell astrocytomas in patients with tuberous sclerosis complex.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 21 Apr 2016

At a glance

  • Drugs Everolimus (Primary)
  • Indications Astrocytoma
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Most Recent Events

    • 21 Apr 2016 Results (n=119) of pooled analysis of 3 studies (NCT00411619, NCT00789828 and NCT00790400) analysing endocrine and menstrual cycle-related events in females presented at the 68th Annual Meeting of the American Academy of Neurology
    • 18 Sep 2015 Results (5-year analysis) published in the Annals of Neurology.
    • 21 Apr 2015 Long-term safety and efficacy results were presented in a final analysis at the 67th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top